A detailed history of Dimensional Fund Advisors LP transactions in Allakos Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 127,992 shares of ALLK stock, worth $107,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,992
Previous 241,950 47.1%
Holding current value
$107,513
Previous $660,000 75.61%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.02 - $3.23 $116,237 - $368,084
-113,958 Reduced 47.1%
127,992 $161,000
Q4 2023

Feb 07, 2024

SELL
$1.72 - $3.18 $465,120 - $859,932
-270,419 Reduced 52.78%
241,950 $660,000
Q3 2023

Nov 09, 2023

SELL
$2.13 - $5.55 $405,733 - $1.06 Million
-190,485 Reduced 27.1%
512,369 $1.16 Million
Q2 2023

Aug 09, 2023

BUY
$3.6 - $5.25 $524,451 - $764,825
145,681 Added 26.15%
702,854 $3.06 Million
Q1 2023

May 12, 2023

BUY
$4.3 - $8.27 $2.25 Million - $4.33 Million
524,113 Added 1585.34%
557,173 $2.48 Million
Q4 2022

Feb 09, 2023

BUY
$5.97 - $8.42 $167 - $235
28 Added 0.08%
33,060 $278,000
Q3 2022

Nov 10, 2022

BUY
$3.02 - $5.84 $2,219 - $4,292
735 Added 2.28%
33,032 $202,000
Q2 2022

Aug 12, 2022

SELL
$2.6 - $6.14 $7,358 - $17,376
-2,830 Reduced 8.06%
32,297 $100,000
Q1 2022

May 13, 2022

SELL
$5.08 - $9.81 $58,262 - $112,510
-11,469 Reduced 24.61%
35,127 $200,000
Q4 2021

Feb 09, 2022

SELL
$8.55 - $111.89 $7,566 - $99,022
-885 Reduced 1.86%
46,596 $456,000
Q3 2021

Nov 12, 2021

SELL
$76.53 - $110.43 $848,488 - $1.22 Million
-11,087 Reduced 18.93%
47,481 $5.03 Million
Q2 2021

Aug 12, 2021

SELL
$85.37 - $114.1 $176,374 - $235,730
-2,066 Reduced 3.41%
58,568 $5 Million
Q1 2021

May 14, 2021

BUY
$109.73 - $153.66 $3.85 Million - $5.39 Million
35,104 Added 137.5%
60,634 $6.96 Million
Q4 2020

Feb 25, 2021

BUY
$79.58 - $152.45 $2.03 Million - $3.89 Million
25,530 New
25,530 $3.57 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $71.2M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.